Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Second Xiangya Hospital of Central South University | OTHER |
| ZhuZhou Central Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
Study Description Brief Summary: The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
Detailed Description: Heart failure is one of the most serious health concerns in the world, and it also remains the most common reason for hospitalization in older individuals. In patients with heart failure, anemia is associated with an increased risk of hospitalization and all-cause mortality. The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure (HF) events and cardiovascular death comparing to placebo in patients with reduced ejection fraction on top of standard of care.
This is an investigator-initiated, interventional, prospective, double-blind study. The primary objective is to investigate whether anemia correction is one of the prerequisites and determinants related to the beneficial effects of dapagliflozin in patients with heart failure. Impact of dapagliflozin treatment on hemoglobin level, heart failure-related readmission and all-cause death will be observed in comparison with placebo in heart failure patients receiving guideline recommended standard therapy during the 3months, 6 months and 1 year follow up.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dapagliflozin | Experimental | Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT |
|
| Placebo | Placebo Comparator | Standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dapagliflozin | Drug | Participants will receive dapagliflozin 10 mg once daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composite number of hospital admissions for Heart Failure (HF) and all-cause death | Total number of deaths and heart failure hospitalizations in one year | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score | The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jianping Zeng, Ph.D. | Contact | +86 15292271982 | 46595842@qq.com |
| Name | Affiliation | Role |
|---|---|---|
| Jianping Zeng, Ph.D. | Xiangtan Central Hospital | Study Chair |
| Shenghua Zhou, Ph.D. | Second Xiangya Hospital of Central South University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xiangtan Central Hospital | Recruiting | Xiangtan | Hunan | 411100 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33779938 | Derived | Zeng J, Zhu Y, Zhao W, Wu M, Huang H, Huang H, Wu C, Zhou X, Zhou S, Wang C, Yin K, Xu F, Cai Z, Li X, Cheng H, Xie Y, Tan Z, Hu X, Liao D, Wang Y. Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients. Cardiovasc Drugs Ther. 2022 Jun;36(3):505-509. doi: 10.1007/s10557-021-07176-0. Epub 2021 Mar 29. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000740 | Anemia |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C529054 | dapagliflozin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Participants will receive placebo 10 mg once daily |
|
| Baselin, 3 months, 6 months, and 1 year |
| Change in 6-minute walk distance (6MWD) | This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. | Baselin, 3 months, 6 months, and 1 year |
| Change in hemoglobin | g/L | Baselin, 3 months, 6 months, and 1 year |
| Chengming Wang, Ph.D. |
| ZhuZhou Central Hospital |
| Study Director |
| Fanghua Xu, M.D. | The First People's Hospital of Xiangtan City | Study Director |
| Zhiqiang Cai, M.D. | Xiangtan People's Hospital | Study Director |
| Chonglun Zhou, M.D. | Xiangxiang People's Hospital | Study Director |